Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX5AP | P20292 | 2/20 | 0.40 |
| ▸ | FEN1 | P39748 | 2/20 | 0.40 |
| ▸ | AOC1 | P19801 | 2/20 | 0.35 |
| ▸ | AOC3 | Q16853 | 2/20 | 0.35 |
| ▸ | CA12 | O43570 | 2/20 | 0.34 |
| ▸ | CA1 | P00915 | 2/20 | 0.34 |
| ▸ | CA2 | P00918 | 2/20 | 0.34 |
| ▸ | CA9 | Q16790 | 2/20 | 0.34 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | GAA | P10253 | 2/20 | 0.33 |
| ▸ | GLA | P06280 | 1/20 | 0.33 |
| ▸ | AURKA | O14965 | 1/20 | 0.32 |
| ▸ | TTK | P33981 | 1/20 | 0.32 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.32 |
| ▸ | INCENP | Q9NQS7 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 2/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.31 |
| ▸ | CYP2E1 | P05181 | 3/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16012024 | 0.82 | ALOX5AP (0.35) | ALOX5APFEN1CA12CA1CA2 | |
| SCHEMBL4698645 | 0.81 | CA12 (0.42) | ALOX5APFEN1AOC3CA12CA1 | |
| SCHEMBL22588118 | 0.80 | ALDH1A1 (0.50) | ALOX5APFEN1KDM4EALDH1A1GAA | |
| SCHEMBL4705428 | 0.79 | ALOX5AP (0.35) | ALOX5APFEN1MAPT | |
| SCHEMBL4701131 | 0.79 | ALOX5AP (0.42) | ALOX5APFEN1MAPT | |
| SCHEMBL4790895 | 0.76 | RAB9A (0.38) | KDM4EALDH1A1GAAMAPTCYP1A2 | |
| SCHEMBL4857523 | 0.75 | ALDH1A1 (0.36) | ALOX5APFEN1ALDH1A1MAPTCYP1A2 | |
| SCHEMBL4790883 | 0.74 | CA12 (0.35) | ALOX5APFEN1CA12CA1CA2 | |
| SCHEMBL4790864 | 0.74 | PTGS1 (0.43) | — | |
| SCHEMBL7852541 | 0.74 | ALDH1A1 (0.51) | AOC1AOC3CA12CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2632261-B1 | INHIBITORS OF HEPATITIS C VIRUS | PRESIDIO PHARMACEUTICALS INC (US) | 2016-07-13 | — | — | EP | disclosed |
| US-9309260-B2 | Inhibitors of hepatitis C virus | PRESIDIO PHARMACEUTICALS, INC. (US) | 2016-04-12 | — | — | US | disclosed |
| US-9309260-B2 | Inhibitors of hepatitis C virus | PRESIDIO PHARMACEUTICALS, INC. (US) | 2016-04-12 | — | — | US | disclosed |
| US-9085587-B2 | Inhibitors of hepatitis C virus | PRESIDIO PHARMACEUTICALS, INC. (US) | 2015-07-21 | — | — | US | disclosed |
| US-9085587-B2 | Inhibitors of hepatitis C virus | PRESIDIO PHARMACEUTICALS, INC. (US) | 2015-07-21 | — | — | US | disclosed |
| US-20130302282-A1 | Inhibitors of Hepatitis C Virus | PRESIDIO PHARMACEUTICALS, INC. (US) | 2013-11-14 | — | — | US | disclosed |
| US-20130302282-A1 | Inhibitors of Hepatitis C Virus | PRESIDIO PHARMACEUTICALS, INC. (US) | 2013-11-14 | — | — | US | disclosed |
| US-20120276051-A1 | INHIBITORS OF HEPATITIS C VIRUS | PRESIDIO PHARMACEUTICALS, INC. (US) | 2012-11-01 | — | — | US | disclosed |
| US-20120276051-A1 | INHIBITORS OF HEPATITIS C VIRUS | PRESIDIO PHARMACEUTICALS, INC. (US) | 2012-11-01 | — | — | US | disclosed |
| US-20120251497-A1 | INHIBITORS OF HEPATITIS C VIRUS | PRESIDIO PHARMACEUTICALS, INC. | 2012-10-04 | — | — | US | disclosed |
| US-20120251497-A1 | INHIBITORS OF HEPATITIS C VIRUS | PRESIDIO PHARMACEUTICALS, INC. | 2012-10-04 | — | — | US | disclosed |
| WO-2012058125-A1 | INHIBITORS OF HEPATITIS C VIRUS | PRESIDIO PHARMACEUTICALS, INC. (US) | 2012-05-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120276051-A1 | INHIBITORS OF HEPATITIS C VIRUS | HAVCR2, LIPC, HCCS | ALOX5AP 2360/4885FEN1 3981/4885AOC1 351/4885 |
| US-20130302282-A1 | Inhibitors of Hepatitis C Virus | HAVCR2, LIPC, HCCS | ALOX5AP 2360/4885FEN1 3981/4885AOC1 351/4885 |
| US-20120251497-A1 | INHIBITORS OF HEPATITIS C VIRUS | HAVCR2, LIPC, HCCS | ALOX5AP 2360/4885FEN1 3981/4885AOC1 351/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.